Overview

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Status:
Recruiting

Trial end date:
2035-02-01

Target enrollment:

Participant gender:

Summary

An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.

Phase:

Phase 1

Details

Lead Sponsor:

Celyad (formerly named Cardio3 BioSciences)
Celyad Oncology SA

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate